HCM
REGN icon

Hudson Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Hudson Capital Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.27M Buy
8,447
+192
+2% +$131K 1.27% 36
2026
Q1 		$6.38M Buy
8,255
+448
+6% +$343K 1.65% 23
2025
Q4 		$6.03M Buy
7,807
+410
+6% +$278K 1.51% 23
2025
Q3 		$4.16M Buy
7,397
+1,292
+21% +$731K 1.1% 42
2025
Q2 		$3.21M Buy
6,105
+647
+12% +$361K 0.91% 43
2025
Q1 		$3.46M Buy
5,458
+497
+10% +$342K 1.06% 43
2024
Q4 		$3.53M Buy
4,961
+357
+8% +$300K 1.1% 41
2024
Q3 		$4.84M Sell
4,604
-125
-3% -$139K 1.54% 26
2024
Q2 		$4.97M Buy
4,729
+88
+2% +$85.3K 1.67% 21
2024
Q1 		$4.47M Sell
4,641
-142
-3% -$135K 1.54% 27
2023
Q4 		$4.2M Sell
4,783
-32
-0.7% -$26.4K 1.52% 23
2023
Q3 		$3.96M Buy
4,815
+323
+7% +$254K 1.58% 21
2023
Q2 		$3.23M Buy
4,492
+74
+2% +$57.1K 1.24% 38
2023
Q1 		$3.63M Buy
4,418
+85
+2% +$64.1K 1.44% 22
2022
Q4 		$3.13M Buy
4,333
+109
+3% +$80.4K 1.24% 26
2022
Q3 		$2.91M Buy
4,224
+226
+6% +$142K 1.45% 17
2022
Q2 		$2.36M Buy
3,998
+221
+6% +$144K 1.12% 28
2022
Q1 		$2.64M Buy
3,777
+144
+4% +$91.1K 1.05% 23
2021
Q4 		$2.29M Sell
3,633
-81
-2% -$49.8K 0.83% 36
2021
Q3 		$2.25M Sell
3,714
-193
-5% -$120K 0.9% 27
2021
Q2 		$2.18M Buy
3,907
+61
+2% +$30.9K 0.9% 34
2021
Q1 		$1.82M Buy
3,846
+130
+3% +$63.3K 0.78% 39
2020
Q4 		$1.79M Sell
3,716
-70
-2% -$37.8K 0.8% 39
2020
Q3 		$2.12M Sell
3,786
-125
-3% -$75.8K 1.04% 30
2020
Q2 		$2.44M Sell
3,911
-1,959
-33% -$1.11M 1.3% 17
2020
Q1 		$2.87M Sell
5,870
-22
-0.4% -$9.07K 1.9% 13
2019
Q4 		$2.21M Sell
5,892
-695
-11% -$234K 1.12% 28
2019
Q3 		$1.83M Buy
6,587
+821
+14% +$243K 1.02% 32
2019
Q2 		$1.8M Buy
5,766
+2,789
+94% +$929K 1.02% 30
2019
Q1 		$1.22M Buy
2,977
+1,061
+55% +$437K 0.74% 44
2018
Q4 		$716K Buy
+1,916
New +$701K 0.52% 49
2018
Q1 		– Sell
-763
Closed -$287K – 84
2017
Q4 		$287K Buy
+763
New +$309K 0.21% 77

Other funds holding REGN

Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
MCI
McDonald Capital Investors Orinda, California $1.37B AUM 1.88% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Retirement Systems of Alabama
Retirement Systems of Alabama Montgomery, Alabama $33.2B AUM 38.15% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.94% 1-Year Est. Return

Hudson Capital Management's REGN Position: Q2 2026 in Review

Hudson Capital Management increased its Regeneron Pharmaceuticals (REGN) stake by 2.3% in Q2 2026, buying an estimated $131K and bringing the position to 8,447 shares worth $5.27M. The position accounts for 1.27% of the portfolio, ranked #36.

Hudson Capital Management first reported a position in REGN in Q4 2017 and has held it in 32 quarters since. The position peaked at $6.38M in Q1 2026. 545 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Hudson Capital Management held 8,447 shares of Regeneron Pharmaceuticals worth $5.27M as of Q2 2026.
  • Hudson Capital Management bought 192 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $131K.
  • Regeneron Pharmaceuticals made up 1.27% of Hudson Capital Management's portfolio in Q2 2026, its #36 holding.
  • Hudson Capital Management first reported a position in Regeneron Pharmaceuticals in Q4 2017 and has held it in 32 quarters since.
  • Hudson Capital Management's Regeneron Pharmaceuticals position peaked at $6.38M in Q1 2026.
  • 545 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Hudson Capital Management's 13F filing for Q2 2026, filed 14 Jul 2026.